Platform Development

Coremed has developed a novel polymer/bio-adhesive drug delivery platform, that allows drug delivery without modifications to a molecule’s three dimensional structure. This platform leaves bioavailability and efficacy intact, while maintaining a molecule’s safety profile. Since 1994, the company has developed a comprehensive product base with key technologies in oral, transmucosal, and transdermal delivery methods. Insulin delivery is the first of many program initiatives currently being developed.

Based on its novel and proprietary platform, Coremed has developed an inhalable form of insulin with a best-in-market bioavailability profile. Alveair™ boasts close to 100% bio-availability, no respiratory side-effects during preliminary human trials, and oral delivery rendering injections unnecessary. Alveair has generated tremendous interest from major pharmaceutical companies and trade organizations.

Coremed has conducted pre-clinical trials of its inhaled insulin technology with over 130 experiments, to show potential in humans. Coremed experimental data and results have been presented at the American Diabetes Association, Endocrine Society Scientific, Experimental Biology, International Congress of Diabetes and American Association of Pharmaceutical Scientists meetings since 2000.

Additionally, Coremed’s Intesulin™ - oral insulin - has been demonstrated to be effective, and based on its pre-clinical trials, has the best efficacy in its class. Preliminary research suggests that Coremed’s drug delivery platform would increase bioavailability for a number of other classes of drugs and allow oral delivery.